Skip to content

Study in Patients With COPD

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00215449
Enrollment
690
Registered
2005-09-22
Start date
Unknown
Completion date
2006-04-30
Last updated
2010-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Keywords

Chronic Obstructive Pulmonary Disease, COPD, formoterol, formoterol fumarate

Brief summary

The purpose of this study is to determine the efficacy and safety of the investigational drug in the treatment of COPD in comparison with a placebo.

Interventions

DRUGFormoterol Fumarate

Sponsors

Dey
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Medical diagnosis of COPD * Current or prior history of cigarette smoking

Exclusion criteria

* Medical diagnosis of asthma * Chest x-ray (CXR) prior to Day 1 diagnostic of significant disease other than COPD * Significant condition or disease other than COPD

Design outcomes

Primary

MeasureTime frame
Measure of lung function

Secondary

MeasureTime frame
Change in lung function, as well as vital signs
Physical Exam results, Adverse Event reporting, etc

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026